Holen Sie sich die Stockscreener-App
31.68
1.34%
-0.43
Handel nachbörslich:
31.67
-0.010
-0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$32.11
Offen:
$31.98
24-Stunden-Volumen:
840.71K
Relative Volume:
0.62
Marktkapitalisierung:
$1.82B
Einnahmen:
$11.13M
Nettoeinkommen (Verlust:
$-105.04M
KGV:
-14.04
EPS:
-2.2565
Netto-Cashflow:
$-81.54M
1W Leistung:
+14.08%
1M Leistung:
+13.55%
6M Leistung:
+305.63%
1J Leistung:
+249.67%
1-Tages-Spanne:
$31.39
$33.15
1-Wochen-Bereich:
$28.30
$33.15
52-Wochen-Spanne:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
31.68 | 1.85B | 11.13M | -105.04M | -81.54M | -2.2565 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones - news.stocktradersdaily.com
Capricor Therapeutics (CAPR) Is Up 7.2% After HOPE-3 Data And PDUFA Update Has The Bull Case Changed? - Sahm
Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone - Sahm
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock - MarketBeat
Capricor Therapeutics (CAPR) director sells 7,529 exercised shares - Stock Titan
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance - MSN
Option exercise and 10b5-1 sales reported by CAPR (NASDAQ: CAPR) - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6%Here's Why - MarketBeat
Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock - marketbeat.com
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock - MarketBeat
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 25,000 Shares of Stock - MarketBeat
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Capricor Therapeutics(CAPR.US) Director Sells US$3.52 Million in Common Stock - Moomoo
Capricor Therapeutics EVP Krasney sells $752k in shares By Investing.com - Investing.com Canada
Capricor Therapeutics director sells $3.5m in shares - Investing.com UK
Capricor Therapeutics director sells $3.5m in shares By Investing.com - Investing.com Australia
Capricor (NASDAQ: CAPR) CFO sells 25K shares after option exercise - Stock Titan
Director at Capricor (NASDAQ: CAPR) sells 115,000 shares via 10b5-1 plan - Stock Titan
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - MSN
Capricor Therapeutics stock jumps as FDA resumes Deramiocel review - MSN
Capricor Therapeutics (NASDAQ: CAPR) proxy: Board nominees, pay and Nippon Shinyaku deals - Stock Titan
[144] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan
Capricor Therapeutics Stock Rises Above 50-Day Average - National Today
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Insider Sell: Is Capricor Therapeutics Inc stock a good dividend stock2026 Price Momentum & Safe Capital Preservation Plans - baoquankhu1.vn
Value Recap: Is Capricor Therapeutics Inc a defensive stock2026 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn
Is Capricor Therapeutics Inc stock a good dividend stock2026 Retail Activity & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Capricor (CAPR) EVP and General Counsel exercises options for 2,500 shares - stocktitan.net
Bull Run: Does Capricor Therapeutics Inc stock benefit from AI growth2026 Support & Resistance & Real-Time Sentiment Analysis - baoquankhu1.vn
Momentum Shift: Is AKAM a top pick in the sectorTreasury Yields & Comprehensive Market Scan Reports - baoquankhu1.vn
Merger Talk: How does Capricor Therapeutics Inc perform in inflationary periods2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Technical Reactions to CAPR Trends in Macro Strategies - Stock Traders Daily
CAPR Technical Analysis | Trend, Signals & Chart Patterns | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor Therapeutics Tokenized Stock (Ondo) price today, CAPRon to USD live price, marketcap and chart - CoinMarketCap
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
Why Capricor Therapeutics (CAPR) Is Down 8.0% After FDA Resumes Deramiocel Review And Phase 3 Update - Sahm
Growth Review: Is Capricor Therapeutics Inc a defensive stock2026 EndofYear Setup & Long-Term Safe Return Strategies - baoquankhu1.vn
Capricor Therapeutics Pipeline Overview: Deramiocel for Muscular Dystrophy and Exosome-Based Vaccine Development (2025-2026) - Minichart
Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insight - GuruFocus
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - 富途牛牛
Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insi - gurufocus.com
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance - Insider Monkey
Capricor Therapeutics 2025 10-K: Revenue $0, EPS $(2.26) - TradingView
Deramiocel DMD program and big Nippon Shinyaku deals at Capricor (NASDAQ: CAPR) - Stock Titan
About Capricor Therapeutics (Ondo Tokenized) - Coinbase
13 Best Hot Stocks to Buy According to Analysts - Insider Monkey
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript - Insider Monkey
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Capricor Therapeutics Inc-Aktie (CAPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sabar Karimah Es | Director |
Apr 02 '26 |
Sale |
32.00 |
7,529 |
240,928 |
0 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):